Disease, Hodgkin Clinical Trial
Official title:
A Phase 1 Dose-Escalation Safety Study of Brentuximab Vedotin in Combination With Multi-Agent Chemotherapy as Frontline Therapy in Patients With Hodgkin Lymphoma
The purpose of this study is to assess the safety profile of brentuximab vedotin in combination with multi-agent chemotherapy in treatment-naive Stage IIa or IIb-IV Hodgkin lymphoma. It is a phase 1, two-arm, open-label dose escalation study designed to define the maximum tolerated dose, pharmacokinetics, immunogenicity and anti-tumor activity of brentuximab vedotin in combination with frontline therapy.
n/a
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00430846 -
Phase I Open-Label Dose Finding Study of SGN-35 for CD30 Positive Hematologic Malignancies
|
Phase 1 | |
| Terminated |
NCT00649584 -
A Phase I Dose Escalation Study of SGN-35 Alone and in Combination With Gemcitabine for CD30-Positive Malignancies
|
Phase 1 | |
| Completed |
NCT00947856 -
A Brentuximab Vedotin Trial for Patients Who Have Previously Participated in a Brentuximab Vedotin Study
|
Phase 2 | |
| Completed |
NCT01026233 -
Cardiac Safety Study of Brentuximab Vedotin (SGN-35)
|
Phase 1 | |
| Completed |
NCT00848926 -
A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin Lymphoma
|
Phase 2 | |
| Completed |
NCT01026415 -
Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35)
|
Phase 1 | |
| Completed |
NCT01100502 -
A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial)
|
Phase 3 | |
| No longer available |
NCT01196208 -
A Treatment-Option Protocol to Provide Brentuximab Vedotin to Eligible Patients Completing Studies SGN35-005 or C25001
|